Clinical Observation of Xuanbai Chengqi Supplementing and Reducing Prescription in Improving Sepsis-Associated Acute Lung Injury

Abstract

Abstract: Objective To observe the clinical efficacy of Xuanbai Chengqi decoction in improving (sepsis-associated acute lung injury, S-ALI). Methods A total of 80 S-ALI patients admitted to Dongzhimen Hospital of Beijing University of Chinese Medicine from January 2020 to December 2021 were selected as research subjects, and were randomly divided into treatment group and control group according to random number table method, with 40 patients in each group. The control group was treated with conventional treatment, and the treatment group was treated with Xuanbai Chengqi supplementing and reducing prescription on the basis of conventional treatment ,both groups were treated for 7 days.. The oxygenation index (PO₂/FiO₂), respiratory rate (R), 24-hour stool volume of 2 groups were observed before and after treatment. Changes of white blood cell (WBC), C-reactive protein (CRP), alanine aminotransferase (ALT), serum creatinine (SCR), acute physiology and chronic health score (APACHE Ⅱ score), serum iron ion (Fe) and other indicators. Results On the 7th day of treatment,the oxygenation index (PO₂/FiO₂), 24-hour stool volume and respiratory rate in the treatment group were higher than those in the control group and the differences were statistically significant (P<0.05); WBC, CRP, APACHE Ⅱ score and Fe in the treatment group were lower than those in the control group, the difference was statistically significant (P<0.05). There were no significant differences in ALT and SCR between the treatment group and the control group. Conclusion Xuanbai Chengqi supplementing and reducing prescription can help the patient to improve lung function, gastrointestinal function, and suppress the inflammatory response. At the same time, the prescription has a certain security to liver and kidney.

Key words: sepsis-associated acute lung Injury, Xuanbai Chengqi supplementing and reducing prescription, oxygenation Index, curative effect

CLC Number:

R278

LIU Hong-shuan, LI Shuo, LIU Qing-quan, YANG Hong. Clinical Observation of Xuanbai Chengqi Supplementing and Reducing Prescription in Improving Sepsis-Associated Acute Lung Injury[J]. ZHONGHUA YANGSHENG BAOJIAN, 2022, 40(20): 1-4.

References

[1] Singer M, Deutschman C S, Seymour C W, et al.The Third International Consensus Definitions for Sepsis and Septic Shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
[2] 刘大为,邱海波,严海.中国重症医学专科资质培训教材[M].2版.北京:人民卫生出版社,2016:112-113.
[3] Xie J F, Wang H L, Kang Y, et al.The epidemiology of sepsis in Chinese ICUs: a national cross-sectional survey[J]. Crit Care Med,2020,48(3): e209-e218.
[4] 吴勉华,王新月.中医内科学[M].9版.北京:中国中医药出版社,2012: 32-35.
[5] 曹钰,柴艳芬,邓颖,等.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].临床急诊杂志,2018,19(9):567-588.
[6] 王佳兴,付鹤鹏,王蓓蕾,等.卡络磺钠通过抑制parkin介导的线粒体自噬减轻脓毒症大鼠的肺损伤[J].中国病理生理杂志,2021,37(8): 1447-1454.
[7] 王宁,丁显飞,崔玉青,等.甲磺酸加贝酯改善脓毒症急性肺损伤大鼠的代谢组学研究[J].中华急诊医学杂志,2022,31(2):191-196.
[8] 何荷,梁隆斌,刘杨,等.绿原酸通过ROS/TXNIP/NLRP3信号通路介导的细胞焦亡途径减轻脓毒症小鼠急性肺损伤[J].中国病理生理杂志,2021,37(8):1455-1461.
[9] 刘锐,林秀玉,孙兆瑞,等.牛磺酸对脓毒症大鼠急性肺损伤的保护作用机制[J].医学研究生学报,2021,34(12):1238-1243.
[10] 李成洁,陈健,吴勇,等.异丙酚抑制甲酰基肽受体1减轻脓毒症诱导的小鼠急性肺损伤[J].现代免疫学,2021,41(6):441-447.
[11] 李秋宇,金醒昉,朱惠容,等.不同剂量红花黄色素A对脓毒症大鼠炎性因子的影响及急性肺损伤的保护作用[J].吉林医学,2021, 42(11):2565-2569.
[12] 孔令博,晏军,张迪,等.中医药治疗脓毒症领域临床优势的探讨[J].中国实验方剂学杂志,2022,28(5):211-218.
[13] 黄晗,李凤芝,李杨,等.灵芝多糖对脓毒症急性肺损伤大鼠肺功能及TLR4/NF-κB通路的影响[J].中草药,2021,52(8):2351-2356.
[14] 段金旗,林艳.姜黄素对脓毒症急性肺损伤大鼠的保护作用[J].中国免疫学杂志,2020,36(19):2380-2383,2388.
[15] 陈新玉,陈晓桦,钟飞雁,等.宣白承气汤保留灌肠在脓毒症肺损伤患者的临床研究[J].中医临床研究,2017,9(36):66-68.
[16] 赖芳,曾瑞峰,张燕,等.益气通腑泻热法治疗脓毒症致急性肺损伤/急性呼吸窘迫综合征的临床研究[J].中医药导报,2021,27(8):75-80.
[17] 潘广涛,刘宇寒,尚罗锐,等.大承气汤通过减轻凋亡对急性肺损伤大鼠的保护机制研究[J].时珍国医国药,2021,32(8):1825-1829.
[18] 王佳,高恒波,林雪容,等.血必净注射液减轻脓毒症诱导的小鼠急性肺损伤的作用及机制[J].华西医学,2021,36(11):1533-1538.
[19] 龚光远,欧红,张文军,等.血必净联合乌司他丁治疗脓毒症急性肺损伤临床研究[J].中国药业,2022,31(4):105-108.
[20] 赵红芳,江其敏,刘清泉.刘清泉教授应用中医药治疗脓毒症的临床经验[J].中国中医急症,2017,26(9):1563-1565.